[{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0.40999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ argenx BV","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ argenx BV"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"Immunoglobulin","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"Immunoglobulin","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"Immunoglobulin","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Medison Pharma"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"HNSA-5487","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"HNSA-5487","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Hansa Biopharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Hansa Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : HNSA-5487 is a company's next-generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity, and redosing potential.

                          Brand Name : HNSA-5487

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 07, 2024

                          Lead Product(s) : HNSA-5487

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Idefirix (Imlifidase), IgG degrader enzyme is being evaluating in the Phase III clinical trial studies for kidney tranplant rejection in highly sensitive patients.

                          Brand Name : Idefirix

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 31, 2024

                          Lead Product(s) : Imlifidase

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated for the treatment of highly sensitized kidney transplant patients.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 14, 2023

                          Lead Product(s) : Imlifidase

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Idefirix (Imlifidase), IgG degrader enzyme in combination with Immunoglobulin antibodies. It is being evaluating in the Phase II clinical trial studies for the treatment of Guillain-Barre Syndrome.

                          Brand Name : Idefirix

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 07, 2023

                          Lead Product(s) : Imlifidase,Immunoglobulin

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated for the treatment of highly sensitized kidney transplant patients.

                          Brand Name : Idefirix

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 11, 2023

                          Lead Product(s) : Imlifidase

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : HNSA-5487 is a next-generation IgG-cleaving enzyme, which is investigated for the treatment of IgG-driven autoimmune disease and experience flares, transplantation where repeat dosing would be beneficial, gene therapy and oncology.

                          Brand Name : HNSA-5487

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 09, 2023

                          Lead Product(s) : HNSA-5487

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated in phase 2 study in anti-neutrophil cytoplasmic antibody ("ANCA")-associated vasculitis.

                          Brand Name : Idefirix

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 19, 2023

                          Lead Product(s) : Imlifidase

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. Idefirix® is conditionally authorized by the European Commission (EC) for the desensitization treatment of highly sensitized adult kidney transplant...

                          Brand Name : Idefirix

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 01, 2023

                          Lead Product(s) : Imlifidase

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Idefirix® (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the treatment of anti-glomerular basement membrane (anti-GBM) disease.

                          Brand Name : Idefirix

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 30, 2023

                          Lead Product(s) : Imlifidase,Cyclophosphamide

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Idefirix (Imlifidase), an enzyme derived from bacterium streptococcus pyogenes, specifically target and cleave all classes of IgG antibodies. Imlifidase is a promising new strategy for desensitization of transplant patients with donor-specific anti-HLA a...

                          Brand Name : Idefirix

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          January 02, 2023

                          Lead Product(s) : Imlifidase

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank